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Abstract
Purpose Being able to function independently in society is an important aspect of quality of life. This ability goes beyond 
self-care, requires higher order cognitive functioning, and is typically measured with instrumental activities of daily living 
(IADL) questionnaires. Cognitive deficits are frequently observed in brain tumour patients, however, IADL is almost never 
assessed because no valid and reliable IADL measure is available for this patient group. Therefore, this measure is currently 
being developed.
Methods This international multicentre study followed European Organisation for Research and Treatment of Cancer 
(EORTC) Quality of Life Group module development guidelines. Three out of four phases are completed: phases (I) gen-
eration of items, (II) construction of the item list, and (III) pre-testing. This paper reports the item selection procedures 
and preliminary psychometric properties of the questionnaire. Brain tumour patients (gliomas and brain metastases), their 
informal caregivers, and health care professionals (HCPs) were included.
Results Phase I (n = 44 patient-proxy dyads and 26 HCPs) generated 59 relevant and important activities. In phase II, the 
activities were converted into items. In phase III (n = 85 dyads), the 59 items were pre-tested. Item selection procedures 
resulted in 32 items. Exploratory factor analysis revealed a preliminary dimensional structure consisting of five scales with 
acceptable to excellent internal consistency (α = 0.73–0.94) and two single items. For three scales, patients with cognitive 
impairments had significantly more IADL problems than patients without impairments.
Conclusion A phase IV validation study is needed to confirm the psychometric properties of the EORTC IADL-BN32 
questionnaire in a larger international sample.
Keywords Daily functioning · Instrumental activities of daily living · IADL · Brain tumour · Questionnaire
Introduction
Brain tumour patients may suffer from various physical, neu-
rological, and neurocognitive impairments. These impair-
ments can have a substantial negative impact on a patient’s 
ability to function in everyday life. Everyday life, or daily 
functioning, can be measured on two levels: basic activities 
of daily living (BADL), which are related to self-mainte-
nance (e.g. eating or dressing), and instrumental activities 
of daily living (IADL), which are related to autonomous 
functioning in society (e.g. household activities or using a 
computer) [1]. IADL rely more heavily on higher order cog-
nitive functioning. Deterioration of cognition is associated 
with worse performance on IADL in the general [2] and 
elderly population [1], and in patients prone to cognitive 
impairments, such as dementia [3].
Despite the fact that preserving the ability to function 
independently as long as possible is particularly important 
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to brain tumour patients due to the incurable nature of the 
disease, and cognitive decline is frequently observed in this 
patient group [4], IADL is almost never measured in brain 
tumour trials or used in clinical practice because no reliable 
and validated measures are available for this patient group 
[5].
One study evaluated the applicability of a reliable and 
valid IADL questionnaire developed for dementia patients 
(i.e. Amsterdam IADL  Questionnaire© (A-IADL-Q)) [3, 
6–8], for the brain tumour population [9], since both patient 
groups experience similar cognitive problems [10, 11]. How-
ever, this instrument did not appear to be entirely relevant 
to brain tumour patients, warranting a brain tumour-specific 
IADL questionnaire.
The general consensus is that patients are the best source 
to rate their functioning and well-being [12]. The A-IADL-
Q, however, was developed as a proxy-based questionnaire, 
as it was hypothesized that cognitive deficits could poten-
tially limit the dementia patients’ ability to rate their own 
level over daily functioning. Brain tumour patients could be 
similarly limited in their ability to rate their level of func-
tioning [13]. Therefore, both a patient-based and proxy-
based version are being developed, analysed, and compared, 
after which it can be decided what version is most appropri-
ate in the brain tumour setting.
The aim of this study is to develop a reliable and valid 
IADL questionnaire that can be implemented in both 
brain tumour trials and clinical practice. Here, the first 




The European Organisation for Research and Treatment of 
Cancer (EORTC) Quality of Life Group (QLG) guidelines 
for module development [14] were followed, consisting of 
four phases: (I) Generation of items, (II) Construction of 
the item list, (III) Pre-testing, and (IV) Field testing. This 
paper reports the results of phases I–III of the developmental 
process (for more details, see Supplemental File 1; Fig. 1).
Study population
The study population consisted of patients with a primary or 
metastatic brain tumour, their informal caregivers as proxies, 
and centre-affiliated health care professionals (HCPs) in the 
field of neuro-oncology. Patients were eligible if they had 
either a histologically confirmed glioma (based on WHO 
2007 criteria) or brain metastases and a histologically con-
firmed primary tumour. Further inclusion criteria were age 
(≥ 18 years) and contact frequency between the patient and 
their proxy (daily or weekly) to ensure a reliable assessment 
of the patient’s daily functioning. The exclusion criterion 
was an insufficient understanding of the official language 
of the country of residence to complete study procedures.
Participant recruitment for phase I took part consecu-
tively in both academic and non-academic outpatient clin-
ics in the Netherlands, Italy, and the United Kingdom and 
for phase III in three European regions, namely Northern 
Europe (The Netherlands and Austria), Southern Europe 
(Italy), an English-speaking region (the United Kingdom, 
i.e. England and Scotland), and a non-European country 
(Japan). Patients meeting the in- and exclusion criteria, who 
were also determined to be physically (i.e. performance sta-
tus) and mentally (i.e. able to consent to research and have 
the mental capacity to complete the study procedures) fit to 
participate by their treating physicians, were approached to 
participate in the study. Following EORTC QLG module 
development guidelines, patient recruitment targeted an even 
distribution across the relevant variables, i.e. tumour type 
(high-grade glioma (HGG)/low-grade glioma (LGG)/1–3 
brain metastases/ > 3 brain metastases) in phase I and, addi-
tionally, the presence of cognitive deficits (present/not pre-
sent) in phase III. Both patient and proxies provided written 
informed consent before participation.
Phases I & II
Phase I aimed to compile an extensive list of IADL relevant 
to brain tumour patients. Five sources of information were 
used: (1) the relevant A-IADL-Q [7] activities from a previ-
ous study (referred to as ‘pilot study’) in glioma patients [9], 
and in accordance with EORTC QLG module development 
guidelines, (2) the literature, (3) the EORTC Item library 
[15], and semi-structured interviews with (4) patients and 
their proxies and (5) HCPs.
During the pilot study (source 1), HCPs (N = 6) judged 
if the activities from the A-IADL-Q could be considered 
as ‘IADL’ using the definition: ‘IADL are complex activi-
ties with little automated skills for which multiple cognitive 
processes are necessary [6]?’. If ≥ 2 HCPs rated an activity 
as not being IADL, it was excluded from further analysis. 
Subsequently, HCPs as well as patients (N = 12) and proxies 
(N = 12) had to rate if the proposed activities were ‘likely 
to be affected in brain tumour patients’. Activities were 
excluded if more than half of all participant groups rated the 
activity as not affected. Finally, patients, proxies, and HCPs 
evaluated if the activities from the A-IADL-Q were ‘clearly 
formulated’. In this case, if an activity was rated unclear 
by > 4 HCPs or > 10 patients or > 10 proxies, the formulation 
was reviewed and the item rephrased.
From a literature review of the electronic databases 
PubMed, Embase, Cochrane, PsycINFO and CINAHL 
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conducted up to April 2017 (source 2) and a review of the 
items in the EORTC Item Library (source 3), additional 
potentially relevant IADL were extracted.
Subsequently, a new group of patients (N = 28), proxies 
(N = 27) and HCPs (N = 18) participated in the semi-struc-
tured interviews. Each IADL activity generated from sources 
1–3 was rated on both relevance and importance (4‐point 
Likert‐scale) by patients and proxies, and missing IADL 
were identified. HCPs also rated the activities on relevance, 
and in addition provided a top 10 of the most important 
IADL activities. Items with an average score of < 2.0 on both 
relevance and importance by either the patients or proxies, 
or with ≥ 6 HCPs rating them as not relevant, were excluded, 
except if they were in ≥ 2 HCPs top 10 most important 
activities.
Finally, another group of patients (N = 2), proxies (N = 2), 
and HCPs (N = 2) cognitively debriefed the remaining items 
resulting from sources 1–5 item generation and selection 
Fig. 1  Flowchart item selection 
phases I-III
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process, and evaluated the appropriateness of the wording of 
the items, and any potential redundancies (for more details, 
see Supplemental File 1).
In Phase II, the activities were converted into question-
naire items and a preliminary IADL questionnaire was con-
structed. Both a patient‐based and proxy‐based version of 
the IADL questionnaire were constructed and subsequently 
translated by the EORTC Translation Unit [16] into the lan-
guages of the countries participating in phase III (English, 
Dutch, Italian, German, and Japanese). The proxy-based ver-
sion consists of the same items but refers to the patient (e.g. 
‘has he/she had difficulties’).
Phase III
Phase III aimed to pre-test the preliminary IADL question-
naire by means of semi-structured interviews and neuropsy-
chological testing. The interview consisted of four parts: (1) 
completion of the IADL questionnaire (4‐point Likert‐scale 
[‘not at all’- ‘very much’], and not applicable), (2) rating 
each activity on relevance and importance (4‐point Likert‐
scale) and acceptability (e.g. not too difficult/confusing/
annoying/upsetting), (3) identification of the 10 most impor-
tant activities, and (4) identification of missing activities. 
For the known-group comparison analysis, patients were 
classified as with or without cognitive impairments using the 
standard neuropsychological test battery used in EORTC tri-
als which comprises three objective tests (six outcomes) and 
a subjective cognitive complaints questionnaire (one out-
come) (for more details, see Supplemental File 1). Patients 
scoring < 2 standard deviations (SD) below the mean of the 
official norm scores on ≥ 2 out of 7 outcomes were classified 
as cognitively impaired.
Item selection
The item selection decision rules in phase III were based 
on EORTC QLG module development guidelines ensuring 
content validity. Cross-cultural validity was preserved by 
using a 3-round stepwise item selection procedure to ensure 
that potential skewed geographical patient population dis-
tributions would not influence item selection (see Table 1 
for all decision rules).
Item retention/omission was based on patient data only. 
However, a sensitivity analysis was performed by repeating 
these steps with proxy data.
Statistical analysis
Descriptive statistics were used to describe the sociodemo-
graphic and clinical characteristics of the participants, as 
well as the quantitative data in phases I and III.
A preliminary evaluation of several psychometric prop-
erties was performed. The content validity was ensured by 
using multiple sources of information to identify IADL 
(phase I), and the subsequent evaluation of relevance, 
importance, acceptability, and completeness of the item list 
in phase III (Table 1). Cross-cultural validity was ensured 
by including participants from different geographical regions 
and the 3-round stepwise item selection procedure. After the 
item selection procedure, structural validity was assessed by 
performing an exploratory factor analysis (EFA; principal 
component analysis with orthogonal rotation (varimax)) due 
to the small sample and no a priori known scale structure. 
This included analysis of eigenvalues, with values > 1 con-
sidered as indication for a factor that should be remained, 
and a scree plot inspection to determine the number of fac-
tors to retain in the EFA. Multiple imputation techniques 
were used for 7% of observations because of the large num-
ber of patients (78%) responding ‘not applicable’ to one 
or more items. As ‘not applicable’ responses are coded as 
missing data, and standard EFA uses listwise deletion, this 
technique prevented that a limited number of patients could 
be included in the analysis.
The EFA resulted in single- and multi-item scales that 
were used in further analyses. The internal consistency of 
the multi-item scales was determined by calculating Cron-
bach’s alpha, with scores between 0.8 > α ≥ 0.7 classified as 
acceptable, 0.9 > α ≥ 0.8 as good, and α ≥ 0.9 as excellent 
[17]. Since there is no ‘gold standard’ to measure IADL 
in brain tumour patients, the criterion validity could not be 
assessed. Instead, construct validation was examined by 
means of known-groups validity. An a priori hypothesis 
was constructed stating that patients classified as cogni-
tively impaired would have higher scores (indicating more 
problems) on the IADL scales/items than patients who were 
classified as cognitively unimpaired. To do so, scale scores 
were calculated based on linear transformation as described 
in the EORTC Scoring Manual [18], and mean differences 
in the groups were compared using Mann–Whitney U tests. 
Congruency between patients and proxies was assessed per 
item (mean difference patient–proxy rating) and per dyad 
(inter-rater reliability) with sub-analyses including patients’ 
cognitive impairment classification (for more details, see 
Supplemental File 1). IBM SPSS version 26.0 was used to 
carry out all statistical analyses [19], and a p value < 0.05 
was considered statistically significant.
Results
Sociodemographic and clinical characteristics of patients 
and their proxies included in phases I and III are described 
in Table 2. In phase I, a total of 44 patients, 43 proxies, and 
26 HCPs were included and in phase III, 85 dyads. Patients 
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with and without cognitive impairments were fairly equal 
distributed among the tumour types (Table 3). Four patients 
could not complete the neuropsychological testing due to 
health issues. 
Phase I & II
The review of the pilot study’s [9] activities (n = 32) recon-
firmed that all items were considered IADL, affected in brain 
tumour patients and clearly defined. The literature search of 
342 unique records resulted in 103 relevant records which 
described 54 unique questionnaires comprising a total of 1376 
items. Out of these 1376 items, 310 were related to IADL. 
Furthermore, 23 IADL were extracted from qualitative studies. 
The review of the items in the EORTC Item Library identified 
526 unique items of which 12 reflected IADL. The 345 IADL 
were clustered and merged based on content, and IADL similar 
to the pilot study items were excluded. On top of the 32 items 
from the pilot study (source 1), an additional 30 IADL were 
identified with sources 2 and 3, resulting in 62 activities. The 
Table 1  Predetermined decision rules for item inclusion, exclusion, and revision for phases I–III
Pt patients, Pr proxies, HCPs health care professionals, IADL instrument activities of daily living
Phases Predetermined decision rules
Phase I
Literature review
  Include Activities that could be considered IADL
 Step 1. Activities ‘pilot study’
  Include 32 pilot study IADL activities
  Exclude ≥ 2 HCPs: Not considered IADL
< 3 Pt/Pr/HCPs: Affected
  Revision ≥ 2 Pt/Pr/HCPs: Unclear; rephrase or, if this was not possible, exclude
 Steps 2 & 3. Semi-structured interviews
  Include ≥ 2 Pt/Pr/HCPs:  New activity generated that could be considered IADL
  Exclude ≥ 6 HCPs: Mean relevance & importance < 2.0 (unless ≥ 2 HCPs in top 
10) or
Not relevant
 Step 4. Cognitive debriefing
  Exclude ≥ 2 Pt/Pr/HCPs: Activities are too similar (redundancy)
  Revision ≥ 2 Pt/Pr/HCPs: Unclear; rephrase or, if this was not possible, exclude
Phase II
Activities converted to items
  Revision Revisions based on recommendations from the Translation Unit to be 
applicable in all languages
Phase III
Newly generated items
  Include ≥2 Pt/Pr: New activity generated that could be considered IADL
 Round 1: Per geographical region
  Exclude Pt: Not in the top 10 most important items and
 < 60% score 3 or 4 on both importance & relevance and
Mean score < 2.0 on difficulty with item (N/A responses excluded)
 Round 2: All geographical regions
  Exclude: (in > 1 region & unless in top 10 most important) Pt: < 60% score 3 or 4 on both importance & relevance or
≥ 75% ‘Not applicable’
 Round 3: All geographical regions
  Exclude: (in > 1 region & unless in top 10 most important) Pt: Prevalence ratio > 30% or
Floor or ceiling effect scores 1&2 or 3&4 were > 20% or
Compliance rate ≤ 95% or
Range ≤ 2 points
 Acceptability
  Revision per region > 5 Pt&Pr: Rate item difficult/confusing/annoying/upsetting
  Revision all regions > 5% Pt&Pr (8.5 Pt&Pr): Rate item difficult/confusing/annoying/upset-
ting
1496 Quality of Life Research (2021) 30:1491–1502
1 3
Table 2  Sociodemographic and clinical characteristics of patients in both phase I and III, as well as the characteristics of their proxies












Dyads (participants) N 23 (45) 21 (42) 44 (87) 45 (90) 40 (80) 85 (170)
Region of residence N (%)
 Northern European 
region
8 (35%) 8 (38%) 16 (36%) 19 (42%) 14 (35%) 33 (39%)
 Southern European 
region
7 (30%) 9 (43%) 16 (36%) 5 (11%) 5 (13%) 10 (12%)
 English-speaking 
region
8 (35%) 4 (19%) 12 (27%) 9 (20%) 9 (23%) 18 (22%)
 Non-European 
region
12 (27%) 12 (30%) 24 (28%)
Sex (male) N (%)
 Patient 14 (61%) 8 (38%) 22 (50%) 20 (44%) 12 (30%) 32 (38%)
 Proxy 10 (45%) 12 (57%) 22 (51%) 19 (42%) 18 (45%) 37 (44%)
Age (yrs) M (SD)
 Patient 55.39 (12.7) 60.75 (12.1) 57.95 (12.6) 54.68 (12.3) 61.48 (11.4) 57.88 (12.3)




 Patient 16 (70%) 12 (57%) 28 (64%) 24 (53%) 25 (63%) 49 (58%)




N (%) 37 (82%) 35 (88%) 72 (85%)
KPS Median (range) 90 (60–100) 90 (40–100) 90 (40–100)
Histology N (%)
 LGG 1 (4%) 1 (4%) 19 (22%) 19 (22%)
 HGG 22 (96%) 22 (96%) 26 (31%) 26 (31%)
 BrM 1–3 17 (81%) 17 (81%) 23 (27%) 23 (27%)
 BrM > 3 4 (19%) 4 (19%) 17 (20%) 17 (20%)
Current active N (%)
treatment
11 (24%) 18 (45%) 29 (34%)
 Chemotherapy 8 (18%) 4 (10%) 12 (14%)
 Radiotherapy 3 (7%) 9 (23%) 12 (14%)
  -Stereotactic 2 (5%) 2 (5%)
  -Whole brain 4 (10%) 4 (10%)
  -Unspecified 3 (8%) 3 (8%)
 Other 0 (0%) 5 (13%) 5 (6%)
Previous treatment N (%)
 Resection 37 (82%) 12 (30%) 49 (58%)
 Re-resection 7 (16%) 2 (5%) 9 (11%)
 Chemotherapy 26 (58%) 4 (10%) 30 (35%)
 Radiotherapy 32 (71%) 29 (73%) 61 (72%)
  -Stereotactic 20 (50%) 20 (50%)
  -Whole brain 7 (18%) 7 (18%)
  -Unspecified 1 (3%) 1 (3%)
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semi-structured interviews generated two new activities (i.e. 
‘being independent’ and ‘doing calculations’) and excluded 
two activities based on HCPs’ assessment of relevance (i.e. 
‘arts and crafts’ and ‘following an instruction manual’). 
The remaining 62 activities were subsequently cognitively 
debriefed, resulting in the exclusion of two redundant activi-
ties (i.e. ‘putting ideas into words’ and ‘engaging socially with 
other people’) and one unclear activity (i.e. ‘getting started 
with a task without prompting’) (Fig. 1) (for more details, see 
Supplemental File 2). In phase II, the remaining 59 activities 
were formulated as items.
Table 2  (continued)












 Left hemisphere 15 (33%) 13 (33%) 28 (33%)
 Right hemisphere 27 (60%) 10 (25%) 37 (44%)
 Midline 2 (4%) 0 (0%) 2 (2%)
 Diffuse 1 (2%) 17 (43%) 18 (21%)
Brain tumour location N (%)
 Frontal 16 (36%) 10 (25%) 26 (31%)
 Temporal 11 (25%) 1 (3%) 12 (14%)
 Occipital 3 (7%) 3 (8%) 6 (7%)
 Parietal 7 (16%) 1 (3%) 8 (9%)
 Intraventricular 1 (2%) 1 (3%) 2 (2%)




 1p/19q-codeletion 6 (13%) 6 (13%)
 1p/19q non-codeletion 8 (18%) 8 (18%)
 Unknown 31 (69%) 31 (69%)
IDH-mutation
 IDH-mutant 8 (18%) 8 (18%)
 IDH-wildtype 12 (27%) 12 (27%)
 Unknown 25 (56%) 25 (56%)
Relation (Partner) N (%) 17 (77%) 16 (76%) 33 (77%) 33 (73%) 28 (70%) 61 (72%)
Contact intensity N (%)
 Living together 18 (82%) 17 (81%) 35 (81%) 38 (84%) 28 (70%) 66 (78%)
 Few times a week 2 (9%) 1 (5%) 3 (7%) 6 (13%) 9 (23%) 15 (18%)
 Weekly 2 (9%) 3 (14%) 5 (12%) 1 (2%) 3 (8%) 4 (5%)
Duration relationship 
(yrs)
M (SD) 28.55 (13.7) 32.58 (15.7) 30.46 (14.6) 31.38 (12.8) 34.83 (15.1) 33.00 (13.9)
*Level of education according to international standard classification of education ranging from 0 (low) to 8 (high) [20]
yrs years, KPS Karnofsky Performance Score, LGG low-grade glioma, HGG high-grade glioma, BrM brain metastases, N number, M mean, SD 
standard deviation
Table 3  Percentage of patients with cognitive impairments (defined 
as z-score more than 2 SD below the control group on at least two 
domains), separately per tumour type
BT brain tumour, LGG low-grade glioma, HGG high-grade glioma, 
BrM brain metastases
Tumour type Missing Cognitively impaired Not cog-
nitively 
impaired
Primary BT 19 (42%) 24 (53%)
 LGG (n = 19) 1 (5%) 8 (42%) 10 (53%)
 HGG (n = 26) 1 (4%) 11 (42%) 14 (54%)
Brain metastases 18 (45%) 20 (50%)
 BrM 1–3 (n = 23) 2 (9%) 11 (48%) 10 (43%)
 BrM > 3 (n = 17) 7 (41%) 10 (59%)




Nine activities suggested by participants could be considered 
IADL and were not covered by the 59-item list, however, 
none were mentioned by ≥ 2 participants, indicating that the 
item list had sufficient coverage.
Item selection
Following the item selection procedure, a total of 10 items 
were excluded in the first round, six items in the second 
round, and an additional 11 items in the third round (Fig. 1; 
for more details, see Supplemental File 3; Fig. 1). This item 
selection procedure resulted in a final list of 32 items.
Proxy ratings (sensitivity analysis) Although item selection 
was based solely on patient data, the item selection proce-
dure was repeated with proxy data. The 59 items from phase 
II were reduced to 33 items, 25 of which were the same as 
those selected based on patient data (data not shown).
Preliminary psychometric properties
Content validity Most of the 32 items were deemed rele-
vant and important; on average, items were rated as ‘quite 
a bit’ or ‘very much’ relevant by 57.2%, and important by 
68.2% of patients. Following the acceptability criteria as 
described in Table  1, N = 24 items needed reviewing (for 
more details, see Supplementary file 3; Table 1). For twelve 
items, ≥ 2 dyads raised the same concern and were accord-
ingly rephrased.
Structural validity An EFA was conducted on the 32 IADL 
items. The Kaiser–Meyer–Olkin measure verified the ade-
quacy of the pooled data: KMO = 0.816 and Bartlett’s test 
of sphericity was significant, χ2(496) = 1858.5, p < 0.001. 
Seven factors had an eigenvalue over Kaiser’s criterion of 
1, which cumulatively explained 70.1% of the variance. The 
slope of the scree plot (Fig. 2), however, flattened after three 
factors. As this is an EFA, we decided to maintain the seven 
factors for further analyses. This resulted in five multi-item 
factors and two single-item factors (Table 4).
Internal consistency The five multi-item factors, or prelimi-
nary scales, were evaluated for their internal consistency, 
which was excellent to acceptable, with Cronbach’s α of 
0.94, 0.88, 0.83, 0.76, and 0.73, respectively.
Known‑group validity The known-group compari-
sons showed significant differences between cognitively 
impaired and unimpaired patients for scales 1 (ranked 
mean (RM) = 48.8 vs. RM = 34.4, p < 0.01), 3 (RM = 49.6 
vs. RM = 33.1, p < 0.01), and 4 (RM = 46.9 vs. RM = 35.0, 
p = 0.02) scale, with worse performance in cognitively 
Fig. 2  Scree plot
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impaired patients. No significant differences between cog-
nitively impaired and unimpaired patients were observed 
for scales 2 (RM = 43.8 vs. RM = 37.8, p = 0.24) and 5 
(RM = 42.5 vs. RM = 35.6, p = 0.17), or the two single items 
14 (RM = 18.6 vs. RM = 17.6, p = 0.78) and 45 (RM = 40.2 
vs. RM = 35.2, p = 0.22).
Congruency Proxies reported on average more problems more 
often than the patients (proxies: 26/32 vs. patients: 4/32), with 
an average mean difference of M = − 0.09 (SD = 0.11) [range 
M = − 0.27 to 0.26]. Patients with cognitive impairments had 
proxies reporting, on average, M = − 0.28 (SD = 0.20) more 
problems than the patients, while patient without cognitive 
impairments reported on average slightly more problems 
M = 0.03 (SD = 0.10) (for more details, see Supplemental File 
3; Table 2). Furthermore, average exact agreement between 
patients and proxies was on average 56.7% [0–100%], with 
inter-rater agreement between κ = − 0.16 and κ = 1.00 (for more 
details, see Supplemental File 3; Table 3) (N/A excluded). For 
patients with and without cognitive impairments, this was 
47.9% [κ = −  0.16 to 1.00] and 64.2% [κ = −  0.16 to 1.00], 
respectively.
Table 4  IADL-BN32 preliminary scale structure: factor loadings of each item within each single- or multi-item scale
Scales Items Factor loadings
Scale 1 Have you had difficulty preparing a meal? 0.81
Have you had difficulty doing maintenance chores in or around the house? 0.79
Have you had difficulty performing household tasks (e.g. cleaning, doing laundry)? 0.78
Have you had difficulty with grocery shopping? 0.78
Have you had difficulty helping others, such as doing small chores or favours for a neighbour, friend or parent? 0.76
Have you had difficulty performing your daily activities without help of others? 0.76
Have you had difficulty taking care of family members (including children)? 0.72
Have you had difficulty participating in traffic (e.g. crossing roads, or driving, cycling, or walking)? 0.68
Have you had difficulty using household appliances? 0.62
Have you had difficulty with your daily responsibilities (i.e. completing daily tasks such as cooking, cleaning, or 
shopping)?
0.57
Have you had difficulty carrying out your hobbies? 0.48
Scale 2 Have you had difficulty expressing yourself (verbally or non-verbally)? 0.79
Have you had difficulty switching between different activities that require concentration, such as watching television 
and participating in a conversation?
0.75
Have you had difficulty finishing tasks that require concentration? 0.74
Have you had difficulty recalling new information? 0.71
Have you had difficulty managing your tasks (e.g. doing tasks in the right order)? 0.66
Have you had difficulty following a one-on-one conversation? 0.57
Have you had difficulty having a one-on-one conversation in noisy surroundings? 0.57
Have you had difficulty finding important personal items (e.g. mobile phone or wallet) around the house? 0.45
Scale 3 Have you had difficulty using a computer/laptop/tablet? 0.73
Have you had difficulty learning new things (e.g. to use a new appliance)? 0.70
Have you had difficulty using a mobile telephone? 0.67
Have you had difficulty writing (e.g. appropriate grammar)? 0.64
Have you had difficulty reading? 0.55
Scale 4 Have you had difficulty making appointments? 0.72
Have you had difficulty making decisions? 0.66
Have you had difficulty doing your personal finances? 0.60
Scale 5 Have you had difficulty participating in social activities? 0.71
Have you had difficulty participating in a group conversation? 0.67
Have you had difficulty organizing a social activity (e.g. a dinner)? 0.58
Scale 6 Have you had difficulty managing your own medication? 0.73
Scale 7 Have you had difficulty doing your job (paid or voluntary)? 0.86
1500 Quality of Life Research (2021) 30:1491–1502
1 3
Discussion
The aim of this study is to develop a reliable and valid 
IADL measure for brain tumour patients. Following the 
procedures of phases I–III of the EORTC module devel-
opment guidelines, ensuring content and cross-cultural 
validity, resulted in the construction of the EORTC IADL-
BN32 questionnaire. Preliminary psychometric property 
analyses showed that the questionnaire has a multidimen-
sional scale structure with acceptable to excellent inter-
nal consistency. Moreover, the current scale structure 
showed known-groups validity regarding cognitive status 
for three out of five scales in this relatively small sample. 
Congruency between patients and proxies showed quite 
some variation between dyads. Agreement between cog-
nitively impaired patients and their proxies was on average 
lower, with their proxies rating IADL issues as slightly 
more severe, compared to cognitive unimpaired patients. 
Therefore, the patient and proxy versions of the EORTC 
IADL-BN32 will be further assessed in phase IV as it 
is still unclear if the proxy-based questionnaire is more 
accurate and preferable in situations where patients are 
cognitively impaired or in poor health.
Limitations of this study were the relatively small sam-
ple and the skewed number of participants per geographi-
cal region due to participant recruitment issues at some 
sites. Results should therefore be interpreted as prelimi-
nary, and further validation in a larger sample in phase 
IV is warranted. A predetermined 3-round stepwise item 
selection procedure was implemented to compensate for 
this imbalance and ensure cross-cultural validity. Further-
more, many patients and proxies reported ‘not applicable’ 
on one or more items resulting in a large proportion of 
missing data, hampering the EFA. This was corrected by 
means of multiple imputation. To facilitate the CFA in the 
phase IV validation, as well as the calculation of the scale/
item scores of the final questionnaire, this response option 
will be omitted in further versions. CFAs in phase IV will 
confirm if the preliminary scale structure is more accu-
rate than, for example, a single factor model. Finally, item 
selection in phase III was based on patient data only, while 
cognitive impairment may result in poorer self-awareness 
of IADL issues [21]. In our sample, however, the sensitiv-
ity analyses with proxy data showed that 25/32 of the same 
items would have been selected.
In conclusion, the preliminary EORTC IADL-BN32 
questionnaire has reasonable preliminary psychometric 
properties, however, further validation in a larger inter-
national sample is warranted. The phase IV validation 
is currently ongoing in ten countries in different global 
regions. Additional European countries (i.e. Germany, 
Norway, Portugal, and Croatia) as well as an additional 
non-European country (i.e. Jordan) are participating in the 
phase IV validation, further enhancing the generalizability 
of our results. The focus of phase IV will be on evaluating 
the scale structure, responsiveness over time, and accept-
ability of the questionnaire. If the EORTC IADL-BN32 
is valid and reliable, it may be a valuable tool in brain 
tumour trials and clinical practice to monitor levels of 
functioning in daily life and may be helpful in evaluating 
the day-to-day impact of changes in cognitive function.
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